Sumitomo Dainippon Pharma Co (4506) Stock Forecast & Price Target

Compare

5 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

4506 Analyst Ratings

Moderate Buy

1 Buy

0 Hold

0 Sell

Based on 1 analysts giving stock ratings to

Sumitomo

Dainippon Pharma Co

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

4506 Stock 12 Month Forecast

Average Price Target

¥2,700.51

▲(18.50% Upside)

Based on 1 Wall Street analysts offering 12 month price targets for Sumitomo Dainippon Pharma Co in the last 3 months. The average price target is ¥2,700.51 with a high forecast of ¥2,700.42 and a low forecast of ¥2,700.42. The average price target represents a 18.50% change from the last price of ¥2,279.00.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"389":"¥389","967":"¥967","1545":"¥1,545","2123":"¥2,123","2701":"¥2,701"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":2700.420495300918,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">¥2.70K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2700.5139386898,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">¥2.70K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2700.420495300918,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">¥2.70K</span>\n  </div></div>","useHTML":true}}],"tickPositions":[389,967,1545,2123,2701],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"May<br/>2025","9":"Aug<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2570,2580.0323457923782,2590.0646915847565,2600.0970373771347,2610.1293831695134,2620.1617289618916,2630.19407475427,2640.226420546648,2650.2587663390264,2660.2911121314046,2670.3234579237833,2680.3558037161615,2690.3881495085398,{"y":2700.420495300918,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2570,2580.039533745369,2590.0790674907385,2600.1186012361077,2610.158134981477,2620.197668726846,2630.2372024722154,2640.2767362175846,2650.316269962954,2660.355803708323,2670.3953374536923,2680.4348711990615,2690.4744049444307,{"y":2700.5139386898,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2570,2580.0323457923782,2590.0646915847565,2600.0970373771347,2610.1293831695134,2620.1617289618916,2630.19407475427,2640.226420546648,2650.2587663390264,2660.2911121314046,2670.3234579237833,2680.3558037161615,2690.3881495085398,{"y":2700.420495300918,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":390,"date":1719792000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":473,"date":1722470400000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":607,"date":1727740800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":563,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":610,"date":1738368000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":713,"date":1743465600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":894,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":805,"date":1748736000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":932,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1236,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1565,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1684.5,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2570,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target¥2,700

Average Price Target¥2,701

Lowest Price Target¥2,700

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Stephen Barker

Jefferies

¥2,700

Buy

18.47%

Upside

Reiterated

12/15/25

Jefferies Sticks to Their Buy Rating for Sumitomo Dainippon Pharma Co (DNPUF)

Seiji Wakao

J.P. Morgan

¥1,600→¥1,880

Buy

-17.51%

Downside

Reiterated

09/05/25

J.P. Morgan Sticks to Their Buy Rating for Sumitomo Dainippon Pharma Co (DNPUF)

Hidemaru Yamaguchi

Citi

¥1,000→¥1,260

Sell

-44.71%

Downside

Reiterated

08/22/25

Citi Sticks to Its Sell Rating for Sumitomo Dainippon Pharma Co (DNPUF)

Shinichiro Muraoka

Morgan Stanley

¥550→¥1,350

Hold

-40.76%

Downside

Upgraded

08/22/25

Sumitomo Pharma upgraded to Equal Weight from Underweight at Morgan StanleySumitomo Pharma upgraded to Equal Weight from Underweight at Morgan Stanley

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Stephen Barker

Jefferies

¥2,700

Buy

18.47%

Upside

Reiterated

12/15/25

Jefferies Sticks to Their Buy Rating for Sumitomo Dainippon Pharma Co (DNPUF)

Seiji Wakao

J.P. Morgan

¥1,600→¥1,880

Buy

-17.51%

Downside

Reiterated

09/05/25

J.P. Morgan Sticks to Their Buy Rating for Sumitomo Dainippon Pharma Co (DNPUF)

Hidemaru Yamaguchi

Citi

¥1,000→¥1,260

Sell

-44.71%

Downside

Reiterated

08/22/25

Citi Sticks to Its Sell Rating for Sumitomo Dainippon Pharma Co (DNPUF)

Shinichiro Muraoka

Morgan Stanley

¥550→¥1,350

Hold

-40.76%

Downside

Upgraded

08/22/25

Sumitomo Pharma upgraded to Equal Weight from Underweight at Morgan StanleySumitomo Pharma upgraded to Equal Weight from Underweight at Morgan Stanley

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Sumitomo Dainippon Pharma Co

1 Month

xxx

Success Rate

6/7 ratings generated profit

Average Return

+19.67%

reiterated a xxx

rating 6 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 85.71% of your transactions generating a profit, with an average return of +19.67% per trade.

3 Months

xxx

Success Rate

6/7 ratings generated profit

Average Return

+45.84%

reiterated a xxx

rating 6 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 85.71% of your transactions generating a profit, with an average return of +45.84% per trade.

1 Year

Stephen BarkerJefferies

Success Rate

6/7 ratings generated profit

Average Return

+114.40%

reiterated a buy rating 6 days ago

Copying Stephen Barker's trades and holding each position for 1 Year would result in 85.71% of your transactions generating a profit, with an average return of +114.40% per trade.

2 Years

xxx

Success Rate

6/7 ratings generated profit

Average Return

+114.40%

reiterated a xxx

rating 6 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 85.71% of your transactions generating a profit, with an average return of +114.40% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

4506 Analyst Recommendation Trends

Rating

Jul 25

Aug 25

Sep 25

Nov 25

Dec 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 4506 has received 5 Buy Ratings, 2 Hold Ratings, and 0 Sell Ratings. 4506 average Analyst price target in the past 3 months is 2,700.51.

Each month's total comprises the sum of three months' worth of ratings.

4506 Financial Forecast

4506 Earnings Forecast

Next quarter’s earnings estimate for 4506 is -¥0.87 with a range of -¥0.87 to -¥0.87. The previous quarter’s EPS was ¥220.63. 4506 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year 4506 has Performed in-line its overall industry.

4506 Sales Forecast

Next quarter’s sales forecast for 4506 is ¥102.70B with a range of ¥94.10B to ¥108.30B. The previous quarter’s sales results were ¥119.12B. 4506 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year 4506 has Performed in-line its overall industry.

4506 Stock Forecast FAQ

What is JP:4506’s average 12-month price target, according to analysts?

Based on analyst ratings, Sumitomo Dainippon Pharma Co Ltd’s 12-month average price target is 2,700.51.

What is JP:4506’s upside potential, based on the analysts’ average price target?

Sumitomo Dainippon Pharma Co Ltd has 18.50% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Sumitomo Dainippon Pharma Co Ltd a Buy, Sell or Hold?

Sumitomo Dainippon Pharma Co Ltd has a consensus rating of Moderate Buy, which is based on 1 buy ratings, 0 hold ratings and 0 sell ratings.

What is Sumitomo Dainippon Pharma Co Ltd’s share price target?

The average share price target for Sumitomo Dainippon Pharma Co Ltd is 2,700.51. This is based on 1 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is ¥2,700.42 ,and the lowest forecast is ¥2,700.42. The average share price target represents 18.50% Increase from the current price of ¥2,279.

What do analysts say about Sumitomo Dainippon Pharma Co Ltd?

Sumitomo Dainippon Pharma Co Ltd’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 1 Wall Streets Analysts.

How can I buy shares of Sumitomo Dainippon Pharma Co Ltd?

To buy shares of JP:4506, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Sumitomo Dainippon Pharma Co (4506) Stock Forecast & Price Target

4506 Analyst Ratings

4506 Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Sumitomo Dainippon Pharma Co

4506 Analyst Recommendation Trends

4506 Financial Forecast

4506 Earnings Forecast

4506 Sales Forecast

4506 Stock Forecast FAQ

Detailed List of Analyst Forecasts